Zeltiq's CoolSculpting
This article was originally published in The Gray Sheet
Executive Summary
Non-invasive fat reduction system will be available in the U.S. immediately after receiving 510(k) clearance, announced Sept. 8. Zeltiq received a CE mark in September 2009 for the controlled cooling technology (1"The Gray Sheet" June 7, 2010). The non-surgical substitute for liposuction is based on the natural biologic susceptibility of fat cells to cold. The CoolSculpting system kills underlying fat cells and does not affect the skin tissue, the firm explains
You may also be interested in...
Financings In Brief
Zeltiq Aesthetics raises $25 million: Fat reduction technology developer raises $25 million in a "Series D" private placement led by Aisling Capital, announced June 2. The funds will help Zeltiq Aesthetics "scale up globally," notes CEO Gordie Nye. The firm received European CE Mark approval last September for non-invasive fat layer reduction with its Zeltiq system, which is based on Cryolipolysis controlled cooling technology. The non-surgical alternative to liposuction relies on the natural biologic vulnerability of fat cells to cold. It "is designed to only kill fat cells and not cause the injury to the skin or other tissue that results from liposuction," the company claims. In the U.S., the system is cleared for dermatologic applications; an application is pending for fat-cell reduction, Zeltiq says. Based in Pleasanton, Calif., Zeltiq has raised $50 million since it was founded in 2005
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.